# The Safety and Immunogenicity of the DNA-GTU Vaccine Administered to HIV-infected Patients on ART vs Placebo

> **NCT02457689** · PHASE1,PHASE2 · COMPLETED · sponsor: **Imperial College London** · enrollment: 30 (actual)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** GTU®-MultiHIV B Clade Vaccine
- **OTHER:** Sodium chloride BP

## Key facts

- **NCT ID:** NCT02457689
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02457689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02457689, "The Safety and Immunogenicity of the DNA-GTU Vaccine Administered to HIV-infected Patients on ART vs Placebo". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02457689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*